Search results
Results from the WOW.Com Content Network
EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer. This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Infusion of R,C,H and O components of R-CHOP. Red flask contains doxorubicin (H), the most toxic component. Prednisolone (P) is administered on the next four or five days intravenously or in tablets. [1] CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:
Hyper-CVAD chemotherapy is generally reserved for use in the treatment of serious and aggressive forms of hematological malignancy. There are serious side effects and complications arising from the administration of the various agents, which require careful management in an appropriate health-care setting.
Antineoplastic agents INN Route [1] Mechanism of action [1] [2] [3] [4] Indications [1] [2] [4] Major toxicities [1] [2] [4] [5]; 1. Cytotoxic antineoplastics: 1.01 ...
Pages in category "Chemotherapy regimens used in lymphoma" The following 22 pages are in this category, out of 22 total. This list may not reflect recent changes .
Despite this, many chemotherapy treatments can also suppress the immune system by causing lymphopenia or impairing lymphocyte function. Integrating immune-based therapies with chemotherapy has the potential to alter the body's overall environment and the local tumor microenvironment, disrupting immune tolerance and suppression pathways.